{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:56:23Z","timestamp":1789167383595,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T00:00:00Z","timestamp":1724284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001782","name":"University of Melbourne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001782","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40259-024-00673-2","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T10:21:56Z","timestamp":1724408516000},"page":"691-702","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment Targets Should Influence Choice of Infliximab Dose Intensification Strategy in Inflammatory Bowel Disease: A Pharmacokinetic Simulation Study"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-1570","authenticated-orcid":false,"given":"Ashish","family":"Srinivasan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"van Langenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Segal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhinav","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard N.","family":"Upton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,22]]},"reference":[{"issue":"9317","key":"673_CR1","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","volume":"359","author":"SB Hanauer","year":"2002","unstructured":"Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn\u2019s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08512-4.","journal-title":"Lancet"},{"issue":"23","key":"673_CR2","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1056\/NEJMoa050516","volume":"353","author":"P Rutgeerts","year":"2005","unstructured":"Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462\u201376. https:\/\/doi.org\/10.1056\/NEJMoa050516.","journal-title":"N Engl J Med"},{"issue":"3","key":"673_CR3","first-page":"760","volume":"104","author":"JP Gisbert","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn\u2019s disease: a review. Am J Gastroenterol. 2009;104(3):760\u20137.","journal-title":"Am J Gastroenterol"},{"key":"673_CR4","doi-asserted-by":"publisher","first-page":"175628482110709","DOI":"10.1177\/17562848211070940","volume":"15","author":"A Srinivasan","year":"2022","unstructured":"Srinivasan A, Gilmore R, van Langenberg D, et al. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn\u2019s disease. Ther Adv Gastroenterol. 2022;15:17562848211070940. https:\/\/doi.org\/10.1177\/17562848211070940.","journal-title":"Ther Adv Gastroenterol"},{"issue":"3","key":"673_CR5","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.cgh.2014.07.029","volume":"13","author":"H Yanai","year":"2015","unstructured":"Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13(3):522\u201330.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"673_CR6","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-3-030-11446-6_20","volume-title":"Biomarkers in inflammatory bowel diseases","author":"A Srinivasan","year":"2019","unstructured":"Srinivasan A, Ding NS, Langenberg DV, et al. Therapeutic drug monitoring in inflammatory bowel disease: optimising therapeutic effectiveness of biologics. In: Ding NS, De Cruz P, editors., et al., Biomarkers in inflammatory bowel diseases. Springer: Berlin; 2019. p. 243\u201355."},{"issue":"11","key":"673_CR7","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/ibd.22902","volume":"18","author":"L Katz","year":"2012","unstructured":"Katz L, Gisbert JP, Manoogian B, et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn\u2019s disease patients with loss of response. Inflamm Bowel Dis. 2012;18(11):2026\u201333. https:\/\/doi.org\/10.1002\/ibd.22902.","journal-title":"Inflamm Bowel Dis"},{"issue":"3","key":"673_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/ibd.20314","volume":"14","author":"F Magro","year":"2008","unstructured":"Magro F, Bastos R, Marques M, et al. Infliximab dose intensification by shortening infusion intervals. Inflamm Bowel Dis. 2008;14(3):432\u20134. https:\/\/doi.org\/10.1002\/ibd.20314.","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"673_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.crohns.2012.03.018","volume":"7","author":"F Baert","year":"2013","unstructured":"Baert F, Glorieus E, Reenaers C, et al. Adalimumab dose escalation and dose de-escalation success rate and predictors in a large national cohort of Crohn\u2019s patients. J Crohns Colitis. 2013;7(2):154\u201360. https:\/\/doi.org\/10.1016\/j.crohns.2012.03.018.","journal-title":"J Crohns Colitis"},{"issue":"3","key":"673_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1365-2036.2010.04523.x","volume":"33","author":"U Kopylov","year":"2011","unstructured":"Kopylov U, Mantzaris GJ, Katsanos KH, et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn\u2019s patients losing response to maintenance dose of infliximab. Alimentery Pharmacol Ther. 2011;33(3):349\u201357. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04523.x.","journal-title":"Alimentery Pharmacol Ther."},{"issue":"3","key":"673_CR11","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/ecco-jcc\/jjx144","volume":"12","author":"A Srinivasan","year":"2018","unstructured":"Srinivasan A, Vasudevan A, McFarlane A, et al. Anti-TNF re-induction is as effective, simpler, and cheaper compared with dose interval shortening for secondary loss of response in Crohn\u2019s disease. J Crohns Colitis. 2018;12(3):280\u20138.","journal-title":"J Crohns Colitis"},{"issue":"4","key":"673_CR12","doi-asserted-by":"publisher","first-page":"550.e2","DOI":"10.1016\/j.cgh.2015.10.025","volume":"14","author":"B Ungar","year":"2016","unstructured":"Ungar B, Levy I, Yavne Y, et al. Optimizing anti-TNF-\u03b1 therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14(4):550.e2-557.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"673_CR13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.cgh.2021.07.053","volume":"20","author":"M De Gregorio","year":"2022","unstructured":"De Gregorio M, Lee T, Krishnaprasad K, et al. Higher anti-tumor necrosis factor-\u03b1 levels correlate with improved radiologic outcomes in Crohn\u2019s perianal fistulas. Clin Gastroenterol Hepatol. 2022;20(6):1306\u201314.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"673_CR14","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.cgh.2020.04.052","volume":"19","author":"P Bossuyt","year":"2021","unstructured":"Bossuyt P, Dreesen E, Rimola J, et al. Infliximab exposure associates with radiologic evidence of healing in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol. 2021;19(5):947\u201354.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"673_CR15","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/ibd\/izy132","volume":"24","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Rakowsky S, Rivera C, et al. Association between serum infliximab trough concentrations during maintenance therapy and biochemical, endoscopic, and histologic remission in Crohn\u2019s disease. Inflamm Bowel Dis. 2018;24(10):2266\u201371.","journal-title":"Inflamm Bowel Dis"},{"issue":"4","key":"673_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1111\/apt.14458","volume":"47","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Rakowsky S, Rivera C, et al. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis. Aliment Pharmacol Ther. 2018;47(4):478\u201384.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"673_CR17","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD. Gastroenterology. 2021;160(5):1570\u201383.","journal-title":"Gastroenterology"},{"issue":"7","key":"673_CR18","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1111\/apt.13970","volume":"45","author":"A Yarur","year":"2017","unstructured":"Yarur A, Kanagala V, Stein D, et al. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn\u2019s disease. Aliment Pharmacol Ther. 2017;45(7):933\u201340.","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"673_CR19","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/jcph.2189","volume":"63","author":"DC Desai","year":"2023","unstructured":"Desai DC, Dherai AJ, Strik A, et al. Personalized dosing of infliximab in patients with inflammatory bowel disease using a Bayesian approach: a next step in therapeutic drug monitoring. J Clin Pharmacol. 2023;63(4):480\u20139.","journal-title":"J Clin Pharmacol"},{"key":"673_CR20","unstructured":"Xu Z, Mould D, Hu C, et al. Population pharmacokinetic analysis of infliximab in pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;1(203)"},{"issue":"2","key":"673_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/00365521.2020.1856405","volume":"56","author":"AS Strik","year":"2021","unstructured":"Strik AS, L\u00f6wenberg M, Mould DR, et al. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021;56(2):145\u201354.","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"673_CR22","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/ajg.2012.363","volume":"108","author":"KS Nanda","year":"2013","unstructured":"Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108(1):40.","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"673_CR23","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","volume":"348","author":"F Baert","year":"2003","unstructured":"Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease. N Engl J Med. 2003;348(7):601\u20138.","journal-title":"N Engl J Med"},{"issue":"1","key":"673_CR24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3748\/wjg.v30.i1.50","volume":"30","author":"AR Srinivasan","year":"2024","unstructured":"Srinivasan AR. Treat to target in Crohn\u2019s disease: a practical guide for clinicians. World J Gastroenterol. 2024;30(1):50\u201369.","journal-title":"World J Gastroenterol"},{"issue":"9","key":"673_CR25","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.crohns.2012.10.019","volume":"7","author":"M Bortlik","year":"2013","unstructured":"Bortlik M, Duricova D, Malickova K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohn\u2019s disease. J Crohns Colitis. 2013;7(9):736\u201343.","journal-title":"J Crohns Colitis"},{"issue":"5","key":"673_CR26","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","volume":"4","author":"NA Kennedy","year":"2019","unstructured":"Kennedy NA, Heap GA, Green HD, et al. Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn\u2019s disease: a prospective, multicentre, cohort study. Lancet Gastroenterol Hepatol. 2019;4(5):341\u201353.","journal-title":"Lancet Gastroenterol Hepatol."},{"issue":"6","key":"673_CR27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1053\/j.gastro.2014.08.035","volume":"147","author":"OJ Adedokun","year":"2014","unstructured":"Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology. 2014;147(6):1296\u2013307.","journal-title":"Gastroenterology"},{"issue":"6","key":"673_CR28","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1111\/apt.15643","volume":"51","author":"DJ Gibson","year":"2020","unstructured":"Gibson DJ, Ward MG, Rentsch C, et al. determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2020;51(6):612\u201328.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"673_CR29","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1111\/jgh.16133","volume":"38","author":"A Srinivasan","year":"2023","unstructured":"Srinivasan A, De Cruz P, Sam M, et al. Dose intensification strategy influences infliximab pharmacokinetics but not clinical response after the same number of doses. J Gastroenterol Hepatol. 2023;38(5):724\u201332.","journal-title":"J Gastroenterol Hepatol"},{"key":"673_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s10928-007-9081-1","volume":"35","author":"TM Post","year":"2008","unstructured":"Post TM, Freijer JI, Ploeger BA, et al. Extensions to the visual predictive check to facilitate model performance evaluation. J Pharmacokinet Pharmacodyn. 2008;35:185\u2013202.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"673_CR31","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1136\/gutjnl-2020-322302","volume":"70","author":"A Srinivasan","year":"2021","unstructured":"Srinivasan A, De Cruz P, Van Langenberg DR. Anti-TNF-associated immunogenicity: use a retroactive drug but a proactive approach. Gut. 2021;70(4):812\u20133.","journal-title":"Gut"},{"key":"673_CR32","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae014","author":"F Magro","year":"2024","unstructured":"Magro F, Fernandes S, Patita M, et al. The influence of subclinical active inflammation on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients. J Crohn\u2019s Colitis. 2024. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjae014. (Epub 19 Jan 2024).","journal-title":"J Crohn's Colitis."},{"issue":"8","key":"673_CR33","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ibd\/izy066","volume":"24","author":"T Greener","year":"2018","unstructured":"Greener T, Kabakchiev B, Steinhart AH, et al. Higher infliximab levels are not associated with an increase in adverse events in inflammatory bowel disease. Inflamm Bowel Dis. 2018;24(8):1808\u201314.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"673_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1080\/00365521.2018.1486882","volume":"53","author":"D Drobne","year":"2018","unstructured":"Drobne D, Kurent T, Golob S, et al. Success and safety of high infliximab trough levels in inflammatory bowel disease. Scand J Gastroenterol. 2018;53(8):940\u20136.","journal-title":"Scand J Gastroenterol"},{"issue":"20","key":"673_CR35","doi-asserted-by":"publisher","first-page":"6173","DOI":"10.3390\/jcm11206173","volume":"11","author":"RD Little","year":"2022","unstructured":"Little RD, Ward MG, Wright E, et al. Therapeutic drug monitoring of subcutaneous infliximab in inflammatory bowel disease\u2014understanding pharmacokinetics and exposure response relationships in a new era of subcutaneous biologics. J Clin Med. 2022;11(20):6173.","journal-title":"J Clin Med"},{"issue":"12","key":"673_CR36","doi-asserted-by":"publisher","first-page":"3188.e2","DOI":"10.1016\/j.cgh.2023.01.004","volume":"21","author":"Z Wang","year":"2023","unstructured":"Wang Z, Verstockt B, Sabino J, et al. Therapeutic drug monitoring can guide the intravenous-to-subcutaneous switch of infliximab and vedolizumab: a simulation study. Clin Gastroenterol Hepatol. 2023;21(12):3188.e2-3190.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"673_CR37","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1053\/j.gastro.2015.02.031","volume":"148","author":"NV Casteele","year":"2015","unstructured":"Casteele NV, Ferrante M, Van Assche G, et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. Gastroenterology. 2015;148(7):1320\u20139.","journal-title":"Gastroenterology"},{"issue":"2","key":"673_CR38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1093\/ecco-jcc\/jjab127","volume":"16","author":"P Bossuyt","year":"2021","unstructured":"Bossuyt P, Pouillon L, Claeys S, et al. Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. J Crohns Colitis. 2021;16(2):199\u2013206. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab127.","journal-title":"J Crohns Colitis"},{"issue":"7","key":"673_CR39","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/ecco-jcc\/jjy039","volume":"12","author":"K Papamichael","year":"2018","unstructured":"Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018;12(7):804\u201310. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy039.","journal-title":"J Crohns Colitis"},{"issue":"12","key":"673_CR40","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1111\/apt.15742","volume":"51","author":"A Srinivasan","year":"2020","unstructured":"Srinivasan A, van Langenberg DR, Little RD, et al. A virtual clinic increases anti-TNF dose intensification success via a treat-to-target approach compared with standard outpatient care in Crohn\u2019s disease. Aliment Pharmacol Ther. 2020;51(12):1342\u201352.","journal-title":"Aliment Pharmacol Ther"}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00673-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-024-00673-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-024-00673-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T20:25:17Z","timestamp":1724876717000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-024-00673-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["673"],"URL":"https:\/\/doi.org\/10.1007\/s40259-024-00673-2","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]},"assertion":[{"value":"24 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was investigator-initiated and did not receive any funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AS has served as a speaker for Sandoz and Arrowtex Pharmaceuticals, and has received advisory fees from Abbvie, Amgen, Arrotex Pharmaceuticals, Pfizer, and Takeda Pharmaceuticals. DvL has received educational grants or research support from Pfizer, Takeda, Ferring, and Shire, and has received consultancy and\/or speaker\u2019s fees from Pfizer, Janssen, AbbVie, Ferring, Vifor and Emerge Health. PDC has served as a consultant, an advisory board member, or a speaker for AbbVie, Baxter, Ferring, Janssen, Celltrion, Pfizer, Emerge Health, Shire and Takeda; is supported by an NHMRC Emerging Leader 2 Fellowship; and has received research support from AbbVie, Ferring, Shire, Janssen, Pfizer and Takeda. JS has received speaker and\/or conference fees from Pfizer, Takeda Pharmaceuticals, BMS, Sandoz, Abbvie, and Celltrion, and an unrestricted grant from Tillots. AV has received advisory fees from Abbvie. RU is a paid contractor for iDose, a developer of Bayes dosing software for infliximab.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"AS conceptualised the study. AS and RU undertook modelling and data analysis. AS reviewed the literature and prepared the original manuscript. All authors critically appraised and approved the final manuscript prior to submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This simulation study did not involve the use of patient data.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The data supporting the findings of this study may be provided upon reasonable request to the corresponding author subject to approval from our Institutional Review Board.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data accessibility statement"}}]}}